Core Insights - Veracyte, Inc. announced new data from the BALANCE trial indicating that the PAM50 molecular signature can predict which patients with recurrent prostate cancer will benefit from apalutamide hormone therapy alongside salvage radiation therapy [1] Company Summary - Veracyte, Inc. is a leading genomic diagnostics company focused on developing innovative tests to improve patient outcomes [1] - The PAM50 biomarker is currently available for Research Use Only on the Decipher GRID platform [1] Industry Context - The findings from the BALANCE trial highlight the growing importance of molecular diagnostics in personalizing cancer treatment, particularly in prostate cancer [1]